Reduction of syndecan‐1 expression during lip carcinogenesis

Martínez, Alejandra; Spencer, M. Loreto; Brethauer, Ursula; Grez, Patricia; Marchesani, Francisco; Rojas, Isolde G.

doi:10.1111/j.1600-0714.2009.00761.x

Cited by 12 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8 Moreover, it seems to be that the CD138 expression is reduced as lip carcinogenesis progresses. 9 Similarly, in the current case, different from CK and EMA, CD138 was faintly expressed.…”

Section: Discussionsupporting

confidence: 49%

“…The CD138 expression seems to correlate significantly with the histological differentiation grade, exhibiting weak and patchy immunostaining in poorly differentiated neoplasms. 8,9 It is known that the cells from the deep invasive front are highly aggressive and less differentiated. In this context, reduced CD138 expression was observed at the deep invasive front in oral SCC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

EBV-negative lymphoepithelial-like carcinoma of the lower lip

et al. 2019

View full text Add to dashboard Cite

Lymphoepithelial-like carcinoma (LEC) is a rare malignant neoplasm, which can be associated with Epstein-Barr virus (EBV) infection. Histologically, LEC is an undifferentiated carcinoma with an intermixed reactive lymphoplasmacytic infiltrate. LEC appears to be an uncommon tumor type of lip carcinoma. An 82-year-old white woman presented a lesion on her lower lip that developed over the last year. The lesion was characterized by ulceration with flat edges, hardened base, painful, and absence of regional lymphadenopathy. Microscopical analysis evidenced an intense inflammatory infiltrate, composed of lymphoplasmacytic cells, associated with scarce pleomorphic epithelial cells. Immunohistochemistry highlighted the LEC cells with strong expression of pan-CK AE1/AE3, EMA, p63, and p53. CD138 was also faintly positive. Ki-67 was >85%. In situ hybridization analysis did not show evidence of EBV. A diagnostic of EBV-negative LEC was made. We present an uncommon type of lip carcinoma, which can represent a diagnostic challenge for clinicians and pathologists.

show abstract

“…8 Moreover, it seems to be that the CD138 expression is reduced as lip carcinogenesis progresses. 9 Similarly, in the current case, different from CK and EMA, CD138 was faintly expressed.…”

Section: Discussionsupporting

confidence: 49%

Section: Discussionmentioning

confidence: 99%

EBV-negative lymphoepithelial-like carcinoma of the lower lip

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The role of syndecans in tumor progression may vary with tumor stage and type [10]. In squamous cell carcinoma, the reduction of syndecan-1 expression is correlated with the progression of carcinogenesis [12], histological grade of malignancy [13], tumor size and the mode of invasion [14]. Furthermore, we also demonstrated evidence that the fragment of syndecan-1 identified was able to induce cell migration.…”

Section: Introductionmentioning

confidence: 64%

Novel Processed Form of Syndecan-1 Shed from SCC-9 Cells Plays a Role in Cell Migration

et al. 2012

View full text Add to dashboard Cite

The extracellular milieu is comprised in part by products of cellular secretion and cell surface shedding. The presence of such molecules of the sheddome and secretome in the context of the extracellular milieu may have important clinical implications. In cancer they have been hypothesized to play a role in tumor growth and metastasis. The objective of this study was to evaluate whether the sheddome/secretome from two cell lines could be correlated with their potential for tumor development. Two epithelial cell lines, HaCaT and SCC-9, were chosen based on their differing abilities to form tumors in animal models of tumorigenesis. These cell lines when stimulated with phorbol-ester (PMA) showed different characteristics as assessed by cell migration, adhesion and higher gelatinase activity. Proteomic analysis of the media from these treated cells identified interesting, functionally relevant differences in their sheddome/secretome. Among the shed proteins, soluble syndecan-1 was found only in media from stimulated tumorigenic cells (SCC-9) and its fragments were observed in higher amount in the stimulated tumorigenic cells than stimulated non-tumorigenic cells (HaCaT). The increase in soluble syndecan-1 was associated with a decrease in membrane-bound syndecan-1 of SCC-9 cells after PMA stimuli. To support a functional role for soluble syndecan-1 fragments we demonstrated that the synthetic syndecan-1 peptide was able to induce cell migration in both cell lines. Taken together, these results suggested that PMA stimulation alters the sheddome/secretome of the tumorigenic cell line SCC-9 and one such component, the syndecan-1 peptide identified in this study, was revealed to promote migration in these epithelial cell lines.

show abstract

“…SDCs are widely recognized to undergo malignancy-associated changes in their expressions in several types of carcinomas, including those of thyroid, breast, colon, skin, stomach and urogenital tract, and SDC1 is recognized to be the best documented prognostic biomarker [ 39 , 41 , 43 , 40 , 46 , 60 - 64 ]. Its expression pattern frequently correlates with the differentiation status of the cells and thereby with their malignancy degree [ 47 , 54 , 65 - 68 ].…”

Section: Discussionmentioning

confidence: 99%

Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors

et al. 2015

View full text Add to dashboard Cite

BackgroundTumour relapse is recognized to be the prime fatal burden in patients affected by head and neck squamous cell carcinoma (HNSCC), but no discrete molecular trait has yet been identified to make reliable early predictions of tumour recurrence. Expression of cell surface proteoglycans (PGs) is frequently altered in carcinomas and several of them are gradually emerging as key prognostic factors.MethodsA PG expression analysis at both mRNA and protein level, was pursued on primary lesions derived from 173 HNSCC patients from whom full clinical history and 2 years post-surgical follow-up was accessible. Gene and protein expression data were correlated with clinical traits and previously proposed tumour relapse markers to stratify high-risk patient subgroups.ResultsHNSCC lesions were indeed found to exhibit a widely aberrant PG expression pattern characterized by a variable expression of all PGs and a characteristic de novo transcription/translation of GPC2, GPC5 and NG2/CSPG4 respectively in 36%, 72% and 71% on 119 cases. Importantly, expression of NG2/CSPG4, on neoplastic cells and in the intralesional stroma (Hazard Ratio [HR], 6.76, p = 0.017) was strongly associated with loco-regional relapse, whereas stromal enrichment of SDC2 (HR, 7.652, p = 0.007) was independently tied to lymphnodal infiltration and disease-related death. Conversely, down-regulated SDC1 transcript (HR, 0.232, p = 0.013) uniquely correlated with formation of distant metastases. Altered expression of PGs significantly correlated with the above disease outcomes when either considered alone or in association with well-established predictors of poor prognosis (i.e. T classification, previous occurrence of precancerous lesions and lymphnodal metastasis). Combined alteration of all three PGs was found to be a reliable predictor of shorter survival.ConclusionsAn unprecedented PG-based prognostic portrait is unveiled that incisively diversifies disease course in HNSCC patients beyond the currently known clinical and molecular biomarkers.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-015-1336-4) contains supplementary material, which is available to authorized users.

show abstract

Reduction of syndecan‐1 expression during lip carcinogenesis

Abstract: The results showed that epithelial syndecan-1 expression is reduced as lip carcinogenesis progresses (NL>AC>lip SCC), suggesting that syndecan-1 could be a useful marker of malignant transformation in the lip.

Cited by 12 publications

References 30 publications

EBV-negative lymphoepithelial-like carcinoma of the lower lip

EBV-negative lymphoepithelial-like carcinoma of the lower lip

Novel Processed Form of Syndecan-1 Shed from SCC-9 Cells Plays a Role in Cell Migration

Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors

Contact Info

Product

Resources

About